Opioid Maker to Pay for Overdose-Antidote Development

A company whose prescription opioid marketing practices are being blamed for sparking the addiction and overdose crisis says it's helping to fund an effort to make a lower-cost overdose antidote. OxyContin maker Purdue Pharma announced Wednesday that it's making a $3.4 million grant to Harm Reduction Therapeutics, a Pittsburgh-based nonprofit, to help develop a low-cost naloxone nasal spray. The announcement comes as lawsuits from local governments blaming Purdue, based in Stamford, Connecticut, and other companies in the drug industry for using deceptive marketing practices to encourage heavy prescribing of the powerful and addictive painkillers. Last week, the number of lawsuits against the industry being overseen by a federal judge topped 1,000. The Cleveland-based judge, Dan Polster, is pushing the industry to settle with the plaintiffs — mostly local governments and Native American tribes — and with state governments, most of which have sued in state court or are conducting a joint investigation. Hundreds of other local governments are also suing in state courts across the country. The sides have had regular settlement discussions, but it's not clear when a deal might be struck in the case, which is complicated by the number of parties and questions on how to assign blame. The U.S. Centers for Disease Control and Prevention estimated that drug overdoses killed a record 72,000 Americans last year, about 10 percent more than in 2016. The majority of the deaths ...
Source: JEMS: Journal of Emergency Medical Services News - Category: Emergency Medicine Tags: Patient Care News Source Type: news

Related Links:

CONCLUSIONS: In this sample, past year non-fatal overdose was common, younger age was a risk factor, and most participants had received a naloxone kit. Further work is needed to understand whether younger age is a risk factor in the general population of pregnant women with opioid use disorder and to identify other potential risk factors for overdose in this population. PMID: 30547833 [PubMed - in process]
Source: Addiction Science and Clinical Practice - Category: Addiction Authors: Tags: Addict Sci Clin Pract Source Type: research
(American College of Neuropsychopharmacology) Synthetic psychoactive drugs have become a serious public health threat in recent years. This is particularly true of the fentanyls, a large family of synthetic opioids, which can be up to 10,000 times more potent than morphine. Synthetic opioids are highly addictive and, because of their potency, often prove fatal: among the roughly 72,000 drug overdose deaths in the US in 2017, some 30,000 were related to synthetic opioids.
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news
Abstract BACKGROUND: In the US, emergency room visits and overdoses related to prescription opioids have soared and the rates of illicit opioid use, including heroin and fentanyl, are increasing. Opioid use disorder (OUD) is associated with higher morbidity and mortality, higher HIV and HCV infection rates, and criminal behavior. Opioid agonist therapy (OAT; methadone and buprenorphine) is proven to be effective in treating OUD and decreasing its negative consequences. While the efficacy of OAT has been established, too few providers prescribe OAT to patients with OUD due to patient, provider, or system factors. W...
Source: Addiction Science and Clinical Practice - Category: Addiction Authors: Tags: Addict Sci Clin Pract Source Type: research
Amid an opioid crisis, police and strangers with cameras are posting raw images of drug users passed out. For those whose bleakest moments now live online, life is never the same.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Drug Abuse and Traffic Addiction (Psychology) Opioids and Opiates Heroin Social Media Facebook Inc YouTube.com Video Recordings, Downloads and Streaming Source Type: news
From the Pennsylvania Press Room: The Wolf Administration will provide naloxone for free to any Pennsylvanian who wants it at nearly 80 locations across the state, primarily at state health centers and county/municipal health departments, on Thursday, December 13 from 11 a.m. to 7 p.m., as part of the administration’s ongoing effort to reduce the number of opioid overdoses and get residents into treatment. “The life-saving medication naloxone is essential for all of us to have on hand, particularly if you have a loved one suffering from opioid-use disorder,” Governor Tom Wolf said. “We want to ensur...
Source: NN/LM Middle Atlantic Region Blog - Category: Databases & Libraries Authors: Tags: Consumer Health Health Professionals In the Region K-12 Public Health Source Type: news
Funding Opportunity RFA-TR-19-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations to develop and implement the use of 3D biofabricated tissue models as novel drug screening platforms and advance pre-clinical discovery and development of non-addictive treatments for nociception, opioid use disorder (OUD) and/or overdose. In particular, support during the UH2 phase is for the application of 3D biofabrication technologies to develop novel multicellular tissue constructs for drug screening by using human iPSC-derived cel...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Funding Opportunity RFA-TR-19-003 from the NIH Guide for Grants and Contracts. Tissue This FOA will provide funding for Investigators to create and test devices that can model the mechanisms or effects of nociception/pain-relevant signaling, addiction, or opioid use disorders (OUDs), using human tissues in in vitro microphysiological systems (MPS). Tissue chips, or microphysiological systems, are useful and promising in vitro human-based screening platforms because they closely mimic in vivo human physiology. Tissue chips have been shown to be capable of modeling normal and diseased physiology that faithfully recapitulate...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
A history of IV drug use or mood disorders increases overdose risk in young patients in treatment for substance abuse.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Source Type: news
ConclusionsAddressing the misuse of opioids among orthopedic patients requires appropriate prescribing practices and long-term support of patients. Collaboration between surgeons and policymaking entities is recognized as an effective population-wide approach to preventing opioid dependence, misuse, and addiction.
Source: HSS Journal - Category: Orthopaedics Source Type: research
“It is borderline genocide,” said DeLuca, 37. “You are allowing [chronic pain patients] to go home and essentially suffer until they kill themselves.” Last year, Lauren DeLuca went to the emergency room in the middle of the night, violently ill and in pain with a pancreatic attack. Despite the fact that she was passing out and vomiting profusely, DeLuca said that she received little help. “I was essentially turned away,” she told The Fix. “Everywhere [I went] I was being accused of lying, accused of making it up.” Over the next three weeks, DeLuca lost 20 pounds, unable to ea...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Disorders Health-related Medications Publishers Substance Abuse The Fix Chronic Pain opioid addiction Opioids Source Type: blogs
More News: Addiction | Centers for Disease Control and Prevention (CDC) | Child Development | Children | Emergency Medicine | Fentanyl | Grants | Hydrocodone | Lawsuits | Legislation | Lortab | Marketing | Overdose | Oxycodone | OxyContin | Pharmaceuticals | Vicodin